Tags

Type your tag names separated by a space and hit enter

Evaluation of long-term co-administration of tobramycin and clarithromycin in a mature biofilm model of cystic fibrosis clinical isolates of Pseudomonas aeruginosa.
Int J Antimicrob Agents. 2009 Oct; 34(4):370-4.IJ

Abstract

Pseudomonas aeruginosa colonisation and chronic lung infection associated with biofilm formation is a major cause of morbidity and mortality in cystic fibrosis (CF) patients. There is thus an urgent need to develop alternative ways to treat biofilm-associated clinical infections. A kinetic study of twice-daily co-administration of the antibiotics tobramycin and clarithromycin was performed over 28 days on 12-day-old mature P. aeruginosa biofilms formed on microplate pegs for 23 clinical isolates of various phenotypes and genotypes to simulate the treatment of CF patients with inhaled tobramycin through aerosolisation (TOBI). Drug activity was assessed by enumeration of persistent bacteria before, during and after treatment. A mature (12-day-old) biofilm model was chosen because a previous study suggested that such a biofilm was a more realistic in vitro model than a 24-h-old biofilm. Synergistic activity of the drug combination was confirmed on biofilms of 9/23 P. aeruginosa isolates. Of these nine isolates, total destruction of the biofilm was observed for five of them. Combination treatment was superior or equivalent to treatment with tobramycin alone, as activity was observed on 47.8% of the isolates with the combination versus 26.1% with tobramycin alone. No correlation was observed between drug susceptibility profiles and the phenotype or genotype of the isolates.

Authors+Show Affiliations

Pharmaceutical Microbiology Laboratory, Institute of Pharmacy, Université Libre de Bruxelles, CP 205/02, Bd. du Triomphe, 1050 Brussels, Belgium. marie.tre-hardy@ulb.ac.beNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Evaluation Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19505804

Citation

Tré-Hardy, Marie, et al. "Evaluation of Long-term Co-administration of Tobramycin and Clarithromycin in a Mature Biofilm Model of Cystic Fibrosis Clinical Isolates of Pseudomonas Aeruginosa." International Journal of Antimicrobial Agents, vol. 34, no. 4, 2009, pp. 370-4.
Tré-Hardy M, Traore H, El Manssouri N, et al. Evaluation of long-term co-administration of tobramycin and clarithromycin in a mature biofilm model of cystic fibrosis clinical isolates of Pseudomonas aeruginosa. Int J Antimicrob Agents. 2009;34(4):370-4.
Tré-Hardy, M., Traore, H., El Manssouri, N., Vanderbist, F., Vaneechoutte, M., & Devleeschouwer, M. J. (2009). Evaluation of long-term co-administration of tobramycin and clarithromycin in a mature biofilm model of cystic fibrosis clinical isolates of Pseudomonas aeruginosa. International Journal of Antimicrobial Agents, 34(4), 370-4. https://doi.org/10.1016/j.ijantimicag.2009.04.010
Tré-Hardy M, et al. Evaluation of Long-term Co-administration of Tobramycin and Clarithromycin in a Mature Biofilm Model of Cystic Fibrosis Clinical Isolates of Pseudomonas Aeruginosa. Int J Antimicrob Agents. 2009;34(4):370-4. PubMed PMID: 19505804.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Evaluation of long-term co-administration of tobramycin and clarithromycin in a mature biofilm model of cystic fibrosis clinical isolates of Pseudomonas aeruginosa. AU - Tré-Hardy,Marie, AU - Traore,Hamidou, AU - El Manssouri,Naïma, AU - Vanderbist,Francis, AU - Vaneechoutte,Mario, AU - Devleeschouwer,Michel Jean, Y1 - 2009/06/07/ PY - 2008/12/16/received PY - 2009/04/17/revised PY - 2009/04/20/accepted PY - 2009/6/10/entrez PY - 2009/6/10/pubmed PY - 2009/10/17/medline SP - 370 EP - 4 JF - International journal of antimicrobial agents JO - Int J Antimicrob Agents VL - 34 IS - 4 N2 - Pseudomonas aeruginosa colonisation and chronic lung infection associated with biofilm formation is a major cause of morbidity and mortality in cystic fibrosis (CF) patients. There is thus an urgent need to develop alternative ways to treat biofilm-associated clinical infections. A kinetic study of twice-daily co-administration of the antibiotics tobramycin and clarithromycin was performed over 28 days on 12-day-old mature P. aeruginosa biofilms formed on microplate pegs for 23 clinical isolates of various phenotypes and genotypes to simulate the treatment of CF patients with inhaled tobramycin through aerosolisation (TOBI). Drug activity was assessed by enumeration of persistent bacteria before, during and after treatment. A mature (12-day-old) biofilm model was chosen because a previous study suggested that such a biofilm was a more realistic in vitro model than a 24-h-old biofilm. Synergistic activity of the drug combination was confirmed on biofilms of 9/23 P. aeruginosa isolates. Of these nine isolates, total destruction of the biofilm was observed for five of them. Combination treatment was superior or equivalent to treatment with tobramycin alone, as activity was observed on 47.8% of the isolates with the combination versus 26.1% with tobramycin alone. No correlation was observed between drug susceptibility profiles and the phenotype or genotype of the isolates. SN - 1872-7913 UR - https://www.unboundmedicine.com/medline/citation/19505804/Evaluation_of_long_term_co_administration_of_tobramycin_and_clarithromycin_in_a_mature_biofilm_model_of_cystic_fibrosis_clinical_isolates_of_Pseudomonas_aeruginosa_ DB - PRIME DP - Unbound Medicine ER -